A：The key financial results for the third quarter of 2026 include a 5.2% year-on-year revenue increase, adjusted for foreign exchange and acquisitions, with organic growth of 4.4%. EBITDA of $187 million grew 9% year on year with an EBITDA margin of 19.9%, and earnings per share (EPS) increased 21% versus the same period last year.

A：Each segment contributed to the overall revenue and EBITDA growth as follows: HHC delivered 6% organic revenue growth with strength in hygiene, beverage labeling, and tape and label; EA had approximately 5% organic revenue growth excluding solar, with continued strength in aerospace and general industries; and BS grew organically by 5% with strength in roofing and leading glass despite softness in wood due to a muted construction environment.

A：The petrochemical supply chain disruption is a defining factor of the operating environment, with supply chains remaining disjointed. The company has been successful in maintaining supply continuity for customers and has adjusted prices to manage raw material costs and protect margins. The expectation is for supply chain normalization to occur well after the conflict subsides.

A：Project Quantum Leap is making good progress and is on track with implementation. The team is focused on disciplined execution. By the end of 2026, the company expects to exit with approximately 62 facilities, which is an improvement towards the goal of 55. Financially, the project targets approximately $75 million of annualized conversion cost savings by the end of 2030, with $25 million already realized through 2026. The program is expected to deliver an additional $20 to $25 million in cost savings in 2027. Capital investments are projected at $150 million over the life of the program, with planned investments of $50 million in 2026 and less than $25 million in 2027. Total one-time cash costs of about $50 million are anticipated, which are expected to be more than offset by proceeds from real estate sales.

A：The updated guidance for fiscal year 2026 anticipates revenue to be in the mid-single digits, with organic revenue expected to increase by low single digits compared to fiscal 2025. Pricing is expected to rise by mid single digits while volume is projected to decrease by low single digits. Adjusted EBITDA is now expected to range between $655 million and $670 million, and adjusted EPS is expected to be in the range of $4.70 to $4.85 per share. The cash flow from operations, excluding Ams related items, is still anticipated to be in the range of $300 to $325 million.

A：The stronger performance in the third quarter was attributed to actions taken to support Quantum Leap and strategic inventory investments for securing raw materials and ensuring customer supply continuity. These factors, along with improved pricing execution and restructuring savings, contributed to the overall positive financial results.

A：The proposed acquisition of Advanced Medical Solutions (AMS) is expected to enhance the portfolio and strengthen the company's position in attractive healthcare markets, supporting long-term growth objectives. Financially, the company remains committed to its deleveraging plan and expects leverage to return to the targeted range of 2.5 to three times within two years of closing the deal. This is supported by the strong cash generation profile of the combined company and further driven by quantum leap.

A：The volume performance in the third quarter turned out to be better than anticipated, with volumes not being as much down as initially expected. The company had anticipated more customer constraints on materials outside of adhesives, but the market was tight rather than short, resulting in slightly better volume performance. Additionally, the demand markets experienced more fluctuation than usual, causing order patterns to be less predictable. Volumes showed strength at the end of the quarter compared to the beginning and have continued to improve.

A：The outlook for volume trends in fiscal year 2027 is uncertain, with volumes projected to remain negative at around down three percent. While the solar business is mentioned as a factor that has impacted volumes, the confidence level for volumes to turn positive in fiscal year 2027 is not clearly indicated. The risk profile for volume growth over the next few quarters is also not specified in the transcript.

A：HP polar will have fully lapped the impact of its exit from the solar business, which was an overhang for Rick Quarters this year. Next year, the closure of AMS and the addition of a higher growth business are expected to present opportunities.

A：The electronics market has been challenged by chip shortages, the auto market by high interest rates impacting residential, and the construction market has remained weak.

A：China is considered a key area of risk for 2027 due to a weak consumer environment and challenges in their electronics export markets. However, the speaker notes that despite these challenges, performance in Asia was still very positive thanks to HHC's ability to grow their business there, particularly in packaging markets.

A：Over the last two years, HHC has faced challenges due to market-wide changes such as the introduction of glps reducing consumption of packaged food and a slowdown in household formation affecting residential home building. The HHC business has struggled because of reduced demand for materials used in packaging and a lack of turnover in homes which leads to decreased demand for new materials.

A：The AMS business announced first half performance with adjusted EBITDA improving by 8% and a 4% revenue increase. The business is expected to grow about 8% a year on average, driven by good organic growth prospects.

A：The EA business performed strongly in the US and Europe but had a real challenge in Asia, especially China, due to a slowdown in electronics shipments. The demand trend line for the EA business has been affected by these regional variances. However, the impact of solar is expected to be fully wrapped by Q4, and the automotive sector has shown resilience with a bounce back in Q3.

A：For the upcoming fiscal year, the company is expecting some carryover of pricing and raw materials in the first half, with more benefits from Quantum Leap flowing through in the second half. The company is continuing to implement price increases where warranted, regionally and based on market segment and technology. The precise impact on EBITDA is not quantified in the transcript.

A：The company expects a positive spread between pricing and raw materials, resulting in a positive gap between pricing and raw material costs next year, although not as significant as this year due to the trailing effect of raw materials. Quantum Leap is expected to contribute about 20 to 25 million of incremental savings, weighted more towards the back half of the year. Additionally, there will be normal inflation merit increases in the $25 million range. The company expects these factors to contribute to the growth of both the top line and bottom line.

A：The $33 million cash flow from sales of manufacturing facilities includes the sale of manufacturing facilities and the associated land, and these facilities will not be leased back by the company.

A：The company aims to cover raw material cost increases and maintain its margins by being judicious and responsible in its pricing strategy. They have been actively adjusting prices, especially in response to raw material cost changes, with an exit price of 7.6% in the quarter, which indicates that they have been able to price in a way that incorporates these costs effectively.

A：Yes, the company is considering shareholder feedback and has made deleveraging a high priority. They are focusing on bringing down debt levels and are undergoing a rigorous portfolio review, which may result in divestitures to accelerate leverage reduction. The company's strategy is also being scrutinized more critically, and the outcome of this review may lead to changes in operational and strategic plans.

A：The company's deleveraging plan includes several key components: rigorous portfolio reviews leading to potential divestitures to reduce leverage, cost reductions in severance and other expenses following the sale of manufacturing facilities, the cash flow benefits from Quantum Leap, improvements in working capital by reducing inventory, reduced capital expenditures, and the completion of the SAP deployment, which will result in less spending on CapEx.

A：The changes in the company's warehouse structure are expected to substantially reduce working capital and inventory, resulting in an additional $35 million benefit in operating cash flow. Additionally, this change will lead to a decrease in CapEx, as the company is expected to spend less on enabling Quantum Leap and the impact of the SAP project deployment.

A：The expected change in capital expenditures (CapEx) for the next year is related to a reduction following the completion of the more significant spending related to Quantum Leap and the sale of the flooring business. The additional capital from AMS is expected to be less than the $20 million previously mentioned, specifically in the teens. Furthermore, the company anticipates a decrease in maintenance capital expenditures by about a third due to shutting down a third of their plants, which would be $15 million in savings.

A：The impact of the company's pricing and production strategy has been positive, with pricing actions taken early on leading to benefits in subsequent quarters. The confidence in expanding margins is supported by the effectiveness of the pricing strategy in the face of a lower volume environment. The benefits from actions taken earlier are flowing through to the third quarter, contributing to the company's confidence in its ability to maintain or expand margins.

A：Margin expansion is attributed to two main factors: the increased pricing power which helped offset the impact of higher raw materials costs, and the Quantum Leap savings which generated $25 million in run-rate savings by the end of the year, ramping up through the year.

A：It is expected that pricing will continue to be positive but at a lower rate than this year, while Quantum Leap will have an even greater positive impact on margins next year.

A：The medical segment, particularly surgical bonding, is considered to be in a high growth medical end market. The number of procedures is expected to increase, and there is a growing number of smaller procedures where adhesive use is likely and accepted, leading to continued strong organic growth at high margin rates.

A：The company has bridge financing in place to assure financing for closing the transaction. The plan is to execute the take-out financing before the close, with a contingent on the close. The term structure is expected to include a combination of short and long-term loan types and possibly unsecured bonds. The financing structure aims for ample amounts to repay quickly, targeting deleveraging swiftly. The cost of debt is currently estimated in the 6.5 to 7% range for fixed rates and around 175 to 200 basis points over sulfur for shorter term loan types. Finalization of the financing is expected before the deal closes.

A：It's difficult to align adhesive business volumes with a collection of macro metrics due to its presence in various end markets and regions. Despite this, the company has a low market share and is able to optimize production with high mileage adhesives, allowing for share gains through technology, which can lead to growth independent of macro trends. This is especially evident in construction, automotive, and mobile phone sectors when those industries are performing poorly.

A：Based on the provided information, it seems the company is guiding for low to mid single-digit EBITDA growth rather than high single digits. Factors include the continuation of pricing volumes down low single digits, cost pressures on raw materials, and a volume outlook that remains under pressure across different end markets. The company also anticipates easier comps from prior year declines. The guidance for next year's financial performance will be detailed in January, and the actual outcome may be influenced by broader macro conditions which will become clearer in the following months. Specific execution benefits are expected to contribute positively to the financial results.

A：The company expects to grow next year, as it has grown in the current and previous years.

A：The new pricing strategy and the Quantum Leap savings, which are on track to deliver $75 million of run-rate savings, are expected to influence EBITDA very favorably.

A：The macro environment presents challenges, and the engineering business is considered somewhat more challenged compared to other parts of the portfolio, which raises questions about the impact on earnings targets and leveraging considerations.

A：The AMS team is making good progress on closing synergies related to facility closures inherited from the acquisition, which is proving very helpful. The market structure is growing rapidly, with the combination of the company's surgical tissue bonding business making them the second largest in the world, which is less reliant on the fluctuations of the industrial or construction sectors.

A：The company does not quantify the synergies but explains that in the case of Bas, the business is significantly integrated into the company as a whole, with many plants producing multiple materials for various market segments. They are considering themselves the best owner but remain open to considering other alternatives that make sense.

A：The company considers that divesting the business unit would involve stranded costs due to shared manufacturing facilities and procurement impacts. They believe they can overcome these challenges depending on the potential valuation of the sale, but the considerations were significant enough to warrant mention.